• 1
    Blann AD, Lip GY. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res. 2001;101:321327.
  • 2
    Ferasin L, Sturgess CP, Cannon MJ, Caney SM, Gruffydd-Jones TJ, Wotton PR. Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994–2001). J Feline Med Surg. 2003; 5:151159.
  • 3
    Laste NJ, Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977–1993. J Am Anim Hosp Assoc. 1995;31:492500.
  • 4
    Atkins CE, Gallo AM, Kurzman ID, Cowen P. Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985–1989). J Am Vet Med Assoc. 1992;201:613618.
  • 5
    Rush JE, Freeman LM, Fenollosa NK, Brown DJ. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc. 2002;220:202207.
  • 6
    MacDonald ML, Rogers QR, Morris JG. Effects of dietary arachidonate deficiency on the aggregation of cat platelets. Comp Biochem Physiol C. 1984;78:123126.
  • 7
    Tablin F, Johnsrude JD, Walker NJ. Evaluation of glycoprotein Ib expression on feline platelets. Am J Vet Res. 2001;62:195201.
  • 8
    Bright JM, Dowers K, Powers BE. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury. Vet Ther. 2003;4:3546.
  • 9
    Hogan DF, Ward MP. Effect of clopidogrel on tissue-plasminogen activator-induced in vitro thrombolysis of feline whole blood thrombi. Am J Vet Res. 2004;65:715719.
  • 10
    Hogan DF, Andrews DA, Talbott KK, Green HW, Ward MP, Calloway BM. Evaluation of antiplatelet effects of ticlopidine in cats. Am J Vet Res. 2004;65:327332.
  • 11
    Behrend EN, Grauer GF, Greco DS, Rose BJ, Thrall MA. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc. 1996;32:1118.
  • 12
    Smith CE, Rozanski EA, Freeman LM, Brown DJ, Goodman JS, Rush JE. Use of low molecular weight heparin in cats: 57 cases (1999–2003). J Am Vet Med Assoc. 2004;225:12371241.
  • 13
    Smith SA, Tobias AH, Jacob KA, Fine DM, Grumbles PL. Arterial thromboembolism in cats: acute crisis in 127 cases (1992–2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med. 2003;17:7383.
  • 14
    Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost. 1995;21 (Suppl 2):106112.
  • 15
    Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195202.
  • 16
    Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res. 2001;62:652658.
  • 17
    Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J. 2003;165:4352.
  • 18
    Wierenga JR, Jandrey KE, Haskins SC, Tablin F. In vitro comparison of the effects of two forms of hydroxyethyl starch solutions on platelet function in dogs. Am J Vet Res. 2007;68:605609.
  • 19
    Keidel A, Mischke R. Clinical evaluation of platelet function analyzer PFA-100 in dogs. Berl Munch Tierarztl Wochenschr. 1998;111:452456.
  • 20
    Meurs KM, Sanchez X, David RM, et al. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet. 2005;14:35873593.
  • 21
    Segura D, Monreal L, Espada Y, et al. Assessment of a platelet function analyzer for horses: reference range and influence of a platelet aggregation inhibitor. Vet J. 2005;170:108112.
  • 22
    Francis JL. Platelet dysfunction detected at high shear in patients with heart valve disease. Platelets. 2000;11:133136.
  • 23
    Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol. 1999;62:165174.
  • 24
    Harrison P, Robinson M, Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol. 2002;24:225232.
  • 25
    Escudero C, Santos M, Bujan J, et al. Optical aggregometry versus the PFA-100: experimental studies in pigs treated with propofol. Platelets. 2001;12:133137.
  • 26
    Barr SC, Ludders JW, Looney AL, Gleed RD, Erb HN. Platelet aggregation in dogs after sedation with acepromazine and atropine and during subsequent general anesthesia and surgery. Am J Vet Res. 1992;53:20672070.
  • 27
    Dwyer SD, Meyers KM. Anesthetics and anticoagulants used in the preparation of rat platelet-rich-plasma alter rat platelet aggregation. Thromb Res. 1986;42:139151.
  • 28
    Fuchs I, Frossard M, Spiel A, et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost. 2006;4:25472552.
  • 29
    Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:13921397.
  • 30
    Serebruany VL, Alford AB, Meister AF, et al. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). Thromb Res. 2001;101:427433.